The stock isn't normally this cheap, and investors should take advantage.DexCom (DXCM -1.27%) is a big name in diabetes care. Its continuous glucose monitors (CGMs) help people track their blood glucose levels.But the stock has been performing poorly this year amid falling growth (the company projects an organic growth rate of around 11% to 13%, far lower than in the past). Investors have also been growing concerned about its prospects, especially if weight loss drugs can lead to a reduction in diabetes cas ...